Tiny Gem Archives

WednesdayDec 17, 2025 10:00 am

Novel Biomarker Could Predict Resistance to Immunotherapy, Study Finds

Scientists at Northwestern Medicine have discovered a biological marker that predicts which cancer patients are more resistant to immunotherapy. Dubbed USP22, the marker also points to a potential treatment target for non-responders. Findings published in The Journal of Clinical Investigation have the potential to transform care for patients whose current options remain limited. Checkpoint blockade immunotherapy prevents harmful interactions between immune cells and cancer cells, keeping T-cells active so they can attack tumors. The approach has revolutionized cancer treatment over the past decade. However, despite early optimism about its potential to become a universal solution, immunotherapy only helps a small fraction of cancer patients. Earlier research showed that low levels of MHC-I proteins on tumor…

MondayDec 15, 2025 9:00 am

US Navy, Palantir Partner to Build AI Submarine

The U.S. Navy has partnered with AI firm Palantir on a $448 million effort to advance computational intelligence and machine automation throughout submarine production. This partnership aims to transform shipyard workflows using sophisticated analytics and prediction tools. Maritime Industrial Base Program leaders alongside Naval Sea Systems Command will direct the Shipbuilding Operating System initiative. The software will consolidate inputs from planning applications, historical records and operational reporting to reveal production slowdowns, enhance design processes and enable preventive problem-solving. Submarine manufacturers, submarine maintenance yards and essential parts providers will get first access, with warship initiatives adopting similar approaches after the approach’s…

WednesdayDec 10, 2025 10:00 am

Optimal Treatment Timing Could Boost Cancer Therapy Efficacy

Administering chemotherapy at specific times could significantly improve outcomes for brain cancer patients. Washington University in St. Louis researchers discovered that treatment timing plays a crucial role in how effectively glioblastoma patients respond to standard drug protocols. Funding came from NCI, Siteman Cancer Center, and National Institutes of Health, with the cancer center operating at WashU Medicine and Barnes-Jewish Hospital. Examining glioblastoma's resistance to treatment despite affecting hundreds of thousands annually, the findings were published in the Journal of Neuro-Oncology. While Temozolomide remains the go-to chemotherapy compound for this malignancy, many patients see limited benefits. Cancer cells typically activate MGMT,…

MondayDec 08, 2025 10:00 am

Study Proposes Overhaul of US Lung Cancer Screening Guidelines

A new analysis is calling for major changes to how the United States screens for lung cancer. Current rules, the study argues, leave out most people who eventually develop the disease. Researchers behind the study say the system used today is far too narrow and fails to capture the full range of Americans who end up at risk. The work, published in JAMA Network Open, examined nearly one thousand lung cancer cases treated at Northwestern Medicine over a five year span. Researchers set out to determine how many of those patients would have qualified for routine CT scans under the…

WednesdayDec 03, 2025 10:00 am

EV Expertise Fuels Successes in Chinese-Made Flying Cars

China's battery-car mastery is propelling its flying vehicle manufacturers ahead of global rivals. Expertise developed through years of electric vehicle production and unmanned aircraft development is giving domestic companies a distinct edge in the nascent aerial mobility market. Aridge, a division of XPeng's automotive business, operates a production facility in Guangzhou capable of assembling one vehicle every thirty minutes at peak capacity. Trial manufacturing launched last month with consumer deliveries planned for next year following more than 7,000 advance orders. Its modular system uses a lightweight six-rotor aircraft that ascends vertically and nests inside a wheeled ground vehicle called the…

WednesdayNov 26, 2025 10:00 am

Nvidia’s Great Earnings Report Fails to Dim AI Investors’ Fears

Nvidia’s great earnings report failed to calm the growing unease around the AI trade, and that tension shaped the mood in markets this week. The company’s blockbuster quarter reaffirmed that demand for AI hardware remains powerful, yet instead of settling the debate, it exposed how sharply divided investors have become over the long term payoff of surging AI investments. Its shares surged at the open on Thursday last week and briefly pulled other AI and tech names with them but the lift evaporated within hours as traders reassessed what the results actually meant. Major indexes traced that same arc, climbing…

FridayNov 21, 2025 10:30 am

Building Global Audience Through Live Competition: How SEGG Media Corporation (NASDAQ: SEGG) Is Scaling Sports Content and Female Motorsport Visibility

Sports.com has surpassed 45 million cumulative live-stream views since launch, fueled by expanding motorsport coverage and global football partnerships Driver Jorden Dolischka became the first woman ever to reach the podium in Gulf Radical Cup history The company secured title sponsorship of Soccerex Miami 2025, placing Sports.com alongside elite clubs and global football leaders ahead of the 2026 FIFA World Cup In an entertainment market dominated by endlessly expanding archives, a different form of content is proving more durable and harder to replicate live competition. Unlike recorded programming, live sports draw audiences at the exact moment events unfold, creating concentrated…

WednesdayNov 19, 2025 10:00 am

Study identifies Biomarker to Predict Success of Immunotherapy, Chemo for Breast Cancer

Researchers from the University of Illinois Urbana-Champaign have discovered a protein that can predict which breast cancer patients will respond well to chemotherapy and immunotherapy. After conducting genome-wide screening in human cancer cells, the research team found that the FGD3 protein was a promising biomarker in determining chemotherapy and immunotherapy efficacy. Patients with high FGD3 levels responded favorably to treatment across all breast cancer types, while those with low levels show poor responses, Professor of biochemistry David J. Shapiro notes. The findings build on 2021 research when the team developed ErSO, an experimental drug that killed 100 percent of breast…

MondayNov 17, 2025 10:00 am

EV Sales in China Set New Record in October

Data from the China Association of Automobile Manufacturers (CAAM) has revealed that China sold 1.7 million electric and plug-in hybrid vehicles in October, setting a new monthly record for the rapidly expanding electric vehicle market. EV makers like BYD and Nio surpassed September sales by roughly 111,000 units, with year-over-year growth hitting 20 percent compared to October 2024. The figure includes exports, which totaled 256,000 vehicles, leaving about 1.5 million for the domestic market. Most of the growth was spurred by increased battery-electric vehicle (BEV) sales. Pure electric sales reached 1.1 million units, up 32% from last year, outpacing the…

FridayNov 14, 2025 9:45 am

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Targets Glioblastoma with Innovative Therapies, Addressing One of Oncology’s Greatest Unmet Needs

Glioblastoma multiforme (“GBM”) is an aggressive brain cancer with limited treatment options, and CEO John Climaco emphasized the company’s commitment to overcoming the blood-brain barrier, a key obstacle in brain cancer therapy. Lead candidate TPI 287, an abeotaxane, has shown early evidence of appearing to cross the blood-brain barrier and producing clinical responses. Phase 2 planning is underway following encouraging data from a Phase 1 combination study with bevacizumab (Avastin). The company’s repurposed global clinical network and regulatory progress position it for potential late-stage development in 2026. TPI 287 holds multiple Orphan Drug Designations, covering gliomas, neuroblastoma, and other CNS-related…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Category: Tiny Gem